<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl0010">
 <label>Table 2</label>
 <caption>
  <p>List of registered potential interactions associated with LPV/r by drug, therapeutic group, severity, frequency, interaction mechanism, effect, and recommendation.</p>
 </caption>
 <alt-text id="at0010">Table 2</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left">Drug (ATC)</th>
    <th align="left">Risk level</th>
    <th align="left">N (%)</th>
    <th align="left">Mechanism</th>
    <th align="left">Effect</th>
    <th align="left">Recommendation
     <xref rid="tblfn0010" ref-type="table-fn">a</xref>
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td colspan="6" align="left">
     <italic>Antiemetics</italic>
    </td>
   </tr>
   <tr>
    <td align="left"> Domperidone</td>
    <td align="left">X</td>
    <td align="left">3 (0.82)</td>
    <td align="left">CYP3A4 inhibition. QT prolongation</td>
    <td align="left">↑ Dc. Cardiovascular toxicity risk, ventricular arrhythmia (TdP)</td>
    <td align="left">Contraindicated. Consider change to metoclopramide</td>
   </tr>
   <tr>
    <td colspan="6" align="left">
     <italic>Antidiabetic</italic>
    </td>
   </tr>
   <tr>
    <td align="left"> Glibenclamide</td>
    <td align="left">C</td>
    <td align="left">2 (0.54)</td>
    <td align="left">CYP3A4 and 2D6 inhibition
     <xref rid="tblfn0015" ref-type="table-fn">b</xref>
    </td>
    <td align="left">↑ Dc. Risk of hypoglycaemia</td>
    <td align="left">Reduce dosage. Monitor glucose.</td>
   </tr>
   <tr>
    <td align="left"> Gliclazide</td>
    <td align="left">C</td>
    <td align="left">1 (0.27)</td>
    <td align="left">Induction of CYP2C9 and 2C19
     <xref rid="tblfn0015" ref-type="table-fn">b</xref>
    </td>
    <td align="left">↓ Dc. Risk of hyperglycaemia</td>
    <td align="left">Increase dosage. Monitor glucose.</td>
   </tr>
   <tr>
    <td align="left"> Repaglinide</td>
    <td align="left">C</td>
    <td align="left">1 (0.27)</td>
    <td align="left">Inhibition of CYP3A4 and OATP1B1 transporter inhibition.</td>
    <td align="left">↑ Dc. Risk of hypoglycaemia</td>
    <td align="left">Reduce dosage. Monitor glucose.</td>
   </tr>
   <tr>
    <td align="left"> Canagliflozin</td>
    <td align="left">D</td>
    <td align="left">1 (0.27)</td>
    <td align="left">Induction of UGT1A9 and 2B4</td>
    <td align="left">↓ Dc. Risk of hyperglycaemia</td>
    <td align="left">If GFR &gt; 60 mL/min, increase dose to 200 mg or 300 mg. Monitor glucose.</td>
   </tr>
   <tr>
    <td align="left"/>
    <td align="left"/>
    <td align="left"/>
    <td align="left"/>
    <td align="left"/>
    <td align="left">If GFR &lt; 60 mL/min, consider another antidiabetic.</td>
   </tr>
   <tr>
    <td colspan="6" align="left">
     <italic>Anticoagulants</italic>
    </td>
   </tr>
   <tr>
    <td align="left"> Apixaban</td>
    <td align="left">D</td>
    <td align="left">5 (1.36)</td>
    <td align="left">CYP3A4 inhibition. P-glycoprotein inhibition</td>
    <td align="left">↑ Dc. Risk of bleeding</td>
    <td align="left">Change to LMWH at therapeutic doses.</td>
   </tr>
   <tr>
    <td align="left"> Rivaroxaban</td>
    <td align="left">X</td>
    <td align="left">3 (0.82)</td>
    <td align="left"/>
    <td align="left"/>
    <td align="left">Contraindicated. Change to LMWH at therapeutic doses.</td>
   </tr>
   <tr>
    <td align="left"> Edoxaban</td>
    <td align="left">D</td>
    <td align="left">3 (0.82)</td>
    <td align="left">P-glycoprotein inhibition</td>
    <td align="left"/>
    <td align="left">Reduce dose to 30 mg or switch to LMWH at therapeutic doses.</td>
   </tr>
   <tr>
    <td align="left"> Acenocoumarol</td>
    <td align="left">C</td>
    <td align="left">11 (2.99)</td>
    <td align="left">CYP2C9 induction</td>
    <td align="left">↓ Dc. Thrombotic risk</td>
    <td align="left">Change to LMWH at therapeutic doses.</td>
   </tr>
   <tr>
    <td colspan="6" align="left">
     <italic>Antiplatelet</italic>
    </td>
   </tr>
   <tr>
    <td align="left"> Clopidogrel</td>
    <td align="left">C</td>
    <td align="left">15 (4.08)</td>
    <td align="left">Inhibition of CYP3A4, (2B6, 2C9 and 1A2)
     <xref rid="tblfn0015" ref-type="table-fn">b</xref>
    </td>
    <td align="left">↓ Dc (active metabolite). Thrombotic risk</td>
    <td align="left">Switch to ASA (monotherapy), switch to prasugrel (dual therapy)</td>
   </tr>
   <tr>
    <td align="left"> Ticagrelor</td>
    <td align="left">X</td>
    <td align="left">2 (0.54)</td>
    <td align="left">CYP3A4 inhibition</td>
    <td align="left">Dc. Risk of bleeding</td>
    <td align="left">Contraindicated. Switch to ASA monotherapy, switch to prasugrel (dual therapy)</td>
   </tr>
   <tr>
    <td colspan="6" align="left">
     <italic>Antihypertensive</italic>
    </td>
   </tr>
   <tr>
    <td align="left"> Doxazosin</td>
    <td align="left">D</td>
    <td align="left">4 (1.09)</td>
    <td align="left">CYP3A4 inhibition</td>
    <td align="left">↑ Dc. Risk of hypotension</td>
    <td align="left">Reduce dosage. Monitor BP</td>
   </tr>
   <tr>
    <td align="left"> Amlodipine</td>
    <td align="left">C</td>
    <td align="left">24 (6.52)</td>
    <td align="left">CYP3A4 inhibition. Prolonged PR</td>
    <td align="left">↑ Dc. Risk of hypotension and AV block</td>
    <td align="left">Reduce dose 50%. Monitor BP and ECG.</td>
   </tr>
   <tr>
    <td align="left"> Nifedipine</td>
    <td align="left">D</td>
    <td align="left">5 (1.36)</td>
    <td align="left"/>
    <td align="left"/>
    <td align="left">Reduce dosage. Monitor BP and ECG.</td>
   </tr>
   <tr>
    <td align="left"> Manidipine</td>
    <td align="left">D</td>
    <td align="left">3 (0.82)</td>
    <td align="left"/>
    <td align="left"/>
    <td align="left">Reduce dosage. Monitor BP and ECG.</td>
   </tr>
   <tr>
    <td align="left"> Lercanidipine</td>
    <td align="left">X</td>
    <td align="left">2 (0.54)</td>
    <td align="left"/>
    <td align="left"/>
    <td align="left">Contraindicated. Change to amlodipine with a 50% dose reduction.</td>
   </tr>
   <tr>
    <td colspan="6" align="left">
     <italic>Other cardiovascular drugs</italic>
    </td>
   </tr>
   <tr>
    <td align="left"> Digoxin</td>
    <td align="left">D</td>
    <td align="left">2 (0.54)</td>
    <td align="left">P-glycoprotein inhibition. Prolonged PR</td>
    <td align="left">↑ Dc. Risk of digitalis poisoning</td>
    <td align="left">Reduce dose between 30%−50% or reduce frequency. Monitor for digoxin levels.</td>
   </tr>
   <tr>
    <td align="left"> Ivabradine</td>
    <td align="left">X</td>
    <td align="left">1 (0.27)</td>
    <td align="left">CYP3A4 inhibition</td>
    <td align="left">↑ Dc. Bradycardia risk</td>
    <td align="left">Contraindicated.</td>
   </tr>
   <tr>
    <td align="left"> Ranolazine (C01EB18)</td>
    <td align="left">X</td>
    <td align="left">2 (0.54)</td>
    <td align="left">CYP3A4 inhibition. QT prolongation</td>
    <td align="left">↑ Dc. Risk of bradycardia, hypotension, ventricular arrhythmia (TdP)</td>
    <td align="left">Contraindicated.</td>
   </tr>
   <tr>
    <td colspan="6" align="left">
     <italic>Antiarrhythmics</italic>
    </td>
   </tr>
   <tr>
    <td align="left"> Amiodarone</td>
    <td align="left">X</td>
    <td align="left">5 (1.36)</td>
    <td align="left">CYP3A4 inhibition. QT prolongation</td>
    <td align="left">↑ Dc. Risk of ventricular arrhythmia</td>
    <td align="left">Contraindicated. Close monitoring, ECG</td>
   </tr>
   <tr>
    <td align="left"> Flecainide</td>
    <td align="left">X</td>
    <td align="left">1 (0.27)</td>
    <td align="left"/>
    <td align="left"/>
    <td align="left"/>
   </tr>
   <tr>
    <td align="left"> Propafenone</td>
    <td align="left">X</td>
    <td align="left">3 (0.82)</td>
    <td align="left">CYP3A4 and 2D6 inhibition
     <xref rid="tblfn0015" ref-type="table-fn">b</xref>
    </td>
    <td align="left"/>
    <td align="left">Close monitoring, ECG</td>
   </tr>
   <tr>
    <td align="left"> Diltiazem</td>
    <td align="left">D</td>
    <td align="left">2 (0.54)</td>
    <td align="left">CYP3A4 inhibition. Prolonged PR</td>
    <td align="left">↑ Dc. Risk of AV block, bradycardia and increased negative inotropic effect</td>
    <td align="left">Reduce dosage. ECG.</td>
   </tr>
   <tr>
    <td align="left"> Verapamil</td>
    <td align="left">D</td>
    <td align="left">6 (1.63)</td>
    <td align="left"/>
    <td align="left"/>
    <td align="left"/>
   </tr>
   <tr>
    <td colspan="6" align="left">Lipid-lowering drugs (statins)</td>
   </tr>
   <tr>
    <td align="left"> Atorvastatin</td>
    <td align="left">D</td>
    <td align="left">26 (7.07)</td>
    <td align="left">CYP3A4 inhibition</td>
    <td align="left">↑ Dc. Risk of liver toxicity and rhabdomyolysis</td>
    <td align="left">Maximum dose 20 mg</td>
   </tr>
   <tr>
    <td align="left"> Lovastatin</td>
    <td align="left">X</td>
    <td align="left">1 (0.27)</td>
    <td align="left"/>
    <td align="left"/>
    <td align="left">Contraindicated. Switch to pravastatin or pitavastatin</td>
   </tr>
   <tr>
    <td align="left"> Simvastatin</td>
    <td align="left">X</td>
    <td align="left">35 (9.51)</td>
    <td align="left"/>
    <td align="left"/>
    <td align="left">Contraindicated. Switch to pravastatin or pitavastatin</td>
   </tr>
   <tr>
    <td align="left"> Rosuvastatin</td>
    <td align="left">D</td>
    <td align="left">3 (0.82)</td>
    <td align="left">BCRP and OATP1B1 transporter inhibition</td>
    <td align="left"/>
    <td align="left">Maximum dose 10 mg</td>
   </tr>
   <tr>
    <td colspan="6" align="left">
     <italic>Urological</italic>
    </td>
   </tr>
   <tr>
    <td align="left"> Tamsulosin</td>
    <td align="left">X</td>
    <td align="left">18 (4.89)</td>
    <td align="left">CYP3A4 and 2D6 inhibition
     <xref rid="tblfn0015" ref-type="table-fn">b</xref>
    </td>
    <td align="left">↑ Dc. Risk of hypotension</td>
    <td align="left">Maximum dose of 0.4 mg/day. Monitor BP</td>
   </tr>
   <tr>
    <td align="left"> Solifenacin</td>
    <td align="left">D</td>
    <td align="left">1 (0.27)</td>
    <td align="left">CYP3A4 inhibition.</td>
    <td align="left">↑ Dc. Risk of anticholinergic toxicity</td>
    <td align="left">Maximum dose 5 mg/day. Monitor anticholinergic effects</td>
   </tr>
   <tr>
    <td colspan="6" align="left">
     <italic>Corticosteroids</italic>
    </td>
   </tr>
   <tr>
    <td align="left"> Methylprednisolone</td>
    <td align="left">D</td>
    <td align="left">23 (6.25)</td>
    <td align="left">CYP3A4 inhibition</td>
    <td align="left">↑ Dc. Risk of Cushing's syndrome</td>
    <td align="left">Reduce dose</td>
   </tr>
   <tr>
    <td align="left"> Prednisone</td>
    <td align="left">C</td>
    <td align="left">5 (1.36)</td>
    <td align="left"/>
    <td align="left"/>
    <td align="left"/>
   </tr>
   <tr>
    <td align="left"> Dexamethasone</td>
    <td align="left">D</td>
    <td align="left">1 (0.27)</td>
    <td align="left">CYP3A4 inhibition (LPV/r)</td>
    <td align="left"/>
    <td align="left"/>
   </tr>
   <tr>
    <td align="left"/>
    <td align="left"/>
    <td align="left"/>
    <td align="left">CYP3A4 induction (dexamethasone)</td>
    <td align="left">↓ LPV/r. Decreased efficacy</td>
    <td align="left"/>
   </tr>
   <tr>
    <td colspan="6" align="left">
     <italic>Antimicrobial</italic>
    </td>
   </tr>
   <tr>
    <td align="left"> Clarithromycin</td>
    <td align="left">D</td>
    <td align="left">6 (1.63)</td>
    <td align="left">CYP3A4 inhibition. QT prolongation</td>
    <td align="left">↑ Dc. Risk of ventricular arrhythmia (TdP)</td>
    <td align="left">If GFR 30−60 ml/min, reduce dose to 500 mg/24 h</td>
   </tr>
   <tr>
    <td align="left"/>
    <td align="left"/>
    <td align="left"/>
    <td align="left"/>
    <td align="left"/>
    <td align="left">If GFR &lt; 30 mL/min, reduce the dose to 250 mg/24 h</td>
   </tr>
   <tr>
    <td align="left"> Metronidazole</td>
    <td align="left">X</td>
    <td align="left">1 (0.27)</td>
    <td align="left">LPV/r oral solution contains alcohol.</td>
    <td align="left">Disulfiram reaction risk</td>
    <td align="left">Contraindicated with the oral solution. No tablets</td>
   </tr>
   <tr>
    <td colspan="6" align="left">
     <italic>Antioestrogens</italic>
    </td>
   </tr>
   <tr>
    <td align="left"> Tamoxifen</td>
    <td align="left">D</td>
    <td align="left">3 (0.82)</td>
    <td align="left">CYP3A4 and 2D6 inhibition
     <xref rid="tblfn0015" ref-type="table-fn">b</xref>
    </td>
    <td align="left">↓ AMC. Decreased oestrogen modulating effect</td>
    <td align="left"/>
   </tr>
   <tr>
    <td colspan="6" align="left">
     <italic>Muscle relaxants</italic>
    </td>
   </tr>
   <tr>
    <td align="left"> Fentanyl iv</td>
    <td align="left">D</td>
    <td align="left">4 (1.09)</td>
    <td align="left">CYP3A4 inhibition</td>
    <td align="left">↑ Dc. Risk of respiratory depression</td>
    <td align="left">Reduce dose to 25−50 mcg/h. Monitor pain (ANI, NOL)</td>
   </tr>
   <tr>
    <td align="left"> Midazolam iv</td>
    <td align="left">D</td>
    <td align="left">24 (6.52)</td>
    <td align="left"/>
    <td align="left">↑ Dc. Risk of respiratory depression and excess sedation.</td>
    <td align="left">Do not exceed &gt; 25 mg/kg/h). Monitor depth of sedation (BIS).</td>
   </tr>
   <tr>
    <td colspan="6" align="left">
     <italic>Opioid pain relievers</italic>
    </td>
   </tr>
   <tr>
    <td align="left"> Fentanyl oral/patch</td>
    <td align="left">D</td>
    <td align="left">2 (0.54)</td>
    <td align="left">CYP3A4 inhibition</td>
    <td align="left">↑ Dc. Risk of sedation and respiratory depression.</td>
    <td align="left">Reduce dose</td>
   </tr>
   <tr>
    <td align="left"> Oxycodone</td>
    <td align="left">D</td>
    <td align="left">1 (0.27)</td>
    <td align="left">CYP3A4 and 2D6 inhibition
     <xref rid="tblfn0015" ref-type="table-fn">b</xref>
    </td>
    <td align="left">↑ Dc. Risk of sedation and respiratory depression.</td>
    <td align="left"/>
   </tr>
   <tr>
    <td colspan="6" align="left">
     <italic>Anticonvulsants</italic>
    </td>
   </tr>
   <tr>
    <td align="left"> Carbamazepine</td>
    <td align="left">D</td>
    <td align="left">1 (0.27)</td>
    <td align="left">CYP3A4 inhibition (LPV/r)</td>
    <td align="left">↑ Dc. CNS toxicity risk.</td>
    <td align="left">Administer LPV/r, at least 2 times a day and consider increasing the dose. Monitor carbamazepine levels and adjust dose.</td>
   </tr>
   <tr>
    <td align="left"/>
    <td align="left"/>
    <td align="left"/>
    <td align="left">CYP3A4 (carbamazepine) induction</td>
    <td align="left">↓ LPV/r. Decreased antiviral effect</td>
    <td align="left"/>
   </tr>
   <tr>
    <td align="left"> Phenytoin</td>
    <td align="left">D</td>
    <td align="left">1 (0.27)</td>
    <td align="left">CYP2C9 and 2C19 induction (LPV/r)</td>
    <td align="left">↓ Dc. Decreased anticonvulsant effect</td>
    <td align="left">Administer LPV/r, at least 2 times a day and consider increasing the dose. Monitor phenytoin levels and adjust dose</td>
   </tr>
   <tr>
    <td align="left"/>
    <td align="left"/>
    <td align="left"/>
    <td align="left">CYP3A (phenytoin) induction</td>
    <td align="left">↓ LPV/r. Decreased antiviral effect</td>
    <td align="left"/>
   </tr>
   <tr>
    <td align="left"> Clonazepam</td>
    <td align="left">D</td>
    <td align="left">5 (1.36)</td>
    <td align="left">CYP3A4 inhibition</td>
    <td align="left">↑ Dc. Risk of sedation and drowsiness.</td>
    <td align="left">Reduce dose</td>
   </tr>
   <tr>
    <td colspan="6" align="left">
     <italic>Hypnotic/sedatives</italic>
    </td>
   </tr>
   <tr>
    <td align="left"> Alprazolam</td>
    <td align="left">D</td>
    <td align="left">10 (2.72)</td>
    <td align="left">Inhibition of CYP3A4 and P-glycoprotein</td>
    <td align="left">↑ Dc. Risk of sedation and respiratory depression.</td>
    <td align="left">Start low dose and increase as needed.</td>
   </tr>
   <tr>
    <td align="left"> Clorazepate</td>
    <td align="left">C</td>
    <td align="left">3 (0.82)</td>
    <td align="left"/>
    <td align="left"/>
    <td align="left">Reduce dosage.</td>
   </tr>
   <tr>
    <td align="left"> Diazepam</td>
    <td align="left">D</td>
    <td align="left">15 (4.08)</td>
    <td align="left">CYP3A4 and C219 inhibition
     <xref rid="tblfn0015" ref-type="table-fn">b</xref>
    </td>
    <td align="left"/>
    <td align="left">Avoid. Reduce dosage.</td>
   </tr>
   <tr>
    <td colspan="6" align="left">
     <italic>Neuroleptics</italic>
    </td>
   </tr>
   <tr>
    <td align="left"> Haloperidol</td>
    <td align="left">D</td>
    <td align="left">8 (2.17)</td>
    <td align="left">CYP3A4, 2D6
     <xref rid="tblfn0015" ref-type="table-fn">b</xref> inhibition and glucuronidation (UGT2B7 &gt; 1A4 and 1A9). QT prolongation.
    </td>
    <td align="left">↑ Dc. CNS toxicity risk. Risk of ventricular arrhythmia (TdP)</td>
    <td align="left">Avoid in the elderly. Reduce dosage. Monitor CNS effects. ECG.</td>
   </tr>
   <tr>
    <td align="left"> Quetiapine</td>
    <td align="left">D</td>
    <td align="left">11 (2.99)</td>
    <td align="left">CYP3A4 and 2D6 inhibition
     <xref rid="tblfn0015" ref-type="table-fn">b</xref>. QT prolongation
    </td>
    <td align="left"/>
    <td align="left">Avoid in the elderly. In schizophrenia, in young patients with high doses, consider reducing 1/6 of the dose. Monitor CNS effects. ECG</td>
   </tr>
   <tr>
    <td colspan="6" align="left">
     <italic>Antidepressants</italic>
    </td>
   </tr>
   <tr>
    <td align="left"> Trazodone</td>
    <td align="left">D</td>
    <td align="left">6 (1.63)</td>
    <td align="left">CYP3A4 inhibition. QT prolongation</td>
    <td align="left">↑ Dc. Risk of CNS, gastric and cardiovascular toxicity.</td>
    <td align="left">Reduce 50%−75% dose</td>
   </tr>
   <tr>
    <td colspan="6" align="left">[0.1−6]
     <italic>Inhaled therapy</italic>
    </td>
   </tr>
   <tr>
    <td align="left"> Budesonide</td>
    <td align="left">D</td>
    <td align="left">42 (11.41)</td>
    <td align="left">CYP3A4 inhibition</td>
    <td align="left">↑ Dc. Risk of Cushing's syndrome.</td>
    <td align="left">Maximum dose 2 inhalations/12 h. Consider beclomethasone</td>
   </tr>
   <tr>
    <td align="left"> Fluticasone</td>
    <td align="left">D</td>
    <td align="left">1 (0.27)</td>
    <td align="left"/>
    <td align="left"/>
    <td align="left">Reduce dosage. Consider beclomethasone</td>
   </tr>
   <tr>
    <td align="left"> Salmeterol</td>
    <td align="left">X</td>
    <td align="left">1 (0.27)</td>
    <td align="left">CYP3A4 inhibition. QT prolongation</td>
    <td align="left">↑ Dc. Cardiovascular toxicity risk: tachycardia and ventricular arrhythmia (TdP)</td>
    <td align="left">Contraindicated. Consider salbutamol</td>
   </tr>
   <tr>
    <td colspan="6" align="left">
     <italic>Antihistamines</italic>
    </td>
   </tr>
   <tr>
    <td align="left"> Ebastine</td>
    <td align="left">D</td>
    <td align="left">1 (0.27)</td>
    <td align="left">CYP3A4 inhibition</td>
    <td align="left">↑ Dc. Risk of drowsiness, xerostomia, and headache</td>
    <td align="left">Reduce dosage. Consider dexchlorpheniramine</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>ASA: acetylsalicylic acid; ANI: analgesia nociception index; AV: atrioventricular; Dc: drug concentration; AMC: active metabolite concentration; CYP: cytochrome P450; ECG: electrocardiogram; GFR: glomerular filtration rate; LMWH: low molecular weight heparin; LPV/r: lopinavir/ritonavir; NOL: nociception index level; PR: PR interval; QT: QT interval; CNS: central nervous system; BP: blood pressure; TdP: torsade de pointes; UGT: UDP-glucuronyl transferases.</p>
  </fn>
 </table-wrap-foot>
 <table-wrap-foot>
  <fn id="tblfn0010">
   <label>a</label>
   <p id="npar0010">Recommendations for concomitant treatment with LPV/r.</p>
  </fn>
 </table-wrap-foot>
 <table-wrap-foot>
  <fn id="tblfn0015">
   <label>b</label>
   <p id="npar0015">At therapeutic concentrations LPV/r does not inhibit: CYP2D6, 2C9, 2C19, 2CE1, 2B6, and 1A2.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
